The neuropeptide calcitonin gene-related peptide is well established as a key player in the pathogenesis of migraine. Clinical studies show calcitonin gene-related peptide levels correlate with migraine attacks, and decreases in this neuropeptide can indicate antimigraine therapy effectiveness. Research has revealed a wide distribution of expression sites for calcitonin gene-related peptide in the central and peripheral nervous system. Of these, the calcitonin gene-related peptide receptor, which binds calcitonin gene-related peptide with high affinity, has attracted growing interest as a viable target for antimigraine therapies. An incentive to pursue such research is the continuing unmet medical need of patients. Triptans have offered some clinical benefit, but many patients do not respond and these drugs have important safety considerations. Initial calcitonin gene-related peptide-focused research led to development of the "gepant" small-molecule calcitonin generelated peptide receptor blockers. Positive efficacy reports concerning the gepants have been tempered by safety findings which led to the discontinuation of some of these agents. Currently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene-related peptide (eptinezumab, galcanezumab, fremanezumab) and the calcitonin generelated peptide receptor (erenumab). To date, these monoclonal antibodies have shown promising efficacy in clinical trials, with no major safety concerns. If ongoing long-term studies show that their efficacy can be maintained, this may herald a new era for effective antimigraine therapies.
INTRODUCTION
For many years, there has been an intense search for biomarkers in primary headaches. 1, 2 During the 1990s, calcitonin gene-related peptide (CGRP), a 37-amino acid neuropeptide, began to attract attention due to findings that tied it closely to actual migraine attacks. 1, 3 Work by independent research groups showed the involvement of the CGRP pathway in migraine pathophysiology and identified it as a viable target for migraine therapies. 1, 4 Antagonism of the CGRP pathway has now been shown to abort migraine pain and offers the exciting potential to prevent migraine.
Other combinations of CLR or CTR with RAMPs can also generate receptors that can be responsive to the CGRP family of peptides (Table 1) . [5] [6] [7] Activation of the CGRP receptor can trigger several signal transduction pathways. 10, 11 The best characterized one is activation of adenylate cyclase, which raises cAMP levels, and in turn activates protein kinase A (PKA) and a downstream phosphorylation cascade. 10 PKA has been implicated in numerous biologic effects of CGRP, such as vasodilation and neural function. 11 Importantly, signaling pathways may vary per cell type, according to which G-proteins and other signaling proteins are expressed.
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At present, the details of signaling pathways related to other CGRP-responsive receptors are poorly understood. 7, 13, 14 To appropriately target CGRP, current research is focused on defining which receptors and signaling pathways are the most clinically relevant to migraine. 7, 9 EXPRESSION AND FUNCTIONAL ROLE OF CGRP AND CGRP RECEPTORS IN THE TRIGEMINOVASCULAR SYSTEM Expression sites of CGRP that may play a role in migraine pathology are known to be widely 5, 6 distributed in the central and peripheral nervous system (Fig. 1) . 4, 5 CGRP is widely expressed in neurons of the cerebral cortex, hippocampus, cerebellum, thalamic nuclei, hypothalamic nuclei, and brainstem nuclei, and some sites also express CGRP receptor. 2 Activation and sensitization of the trigeminovascular system (TGVS) are closely linked to migraine pathophysiology. 15 The TGVS represents a major control center for the regulation of blood flow in the head and is a key area for the transmission of pain. 7 CGRP is released from trigeminal nerves in migraine and trigeminal nerve activation results in antidromic release of CGRP to cause non-endothelium-mediated vasodilation. 16 The most abundant neuropeptide in the trigeminal nerve is CGRP, which is expressed in 35-50% of neurons in the trigeminal ganglia. 3, 17 Although CGRP is released into the plasma, it is rapidly degraded (T 1/2 < 10 min), implying that its main effects are exerted close to its release site in the vessel wall.
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The distribution of CLR and RAMP1, the main constituents of the CGRP receptor, has been mapped to the cytoplasm of trigeminal neurons, at peripheral sites on the intracranial vasculature, in the dura mater and in the brainstem (Fig. 1 ).
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RAMP1 and CLR appear together predominantly in some of the neurons and satellite glial cells, and also in vascular smooth muscle cells but not in the endothelium. 1 While the pattern of these receptor elements may resemble that of CGRP expression, co-expression of RAMP1 and CLR with CGRP itself is rare. 1 Immunohistochemistry reveals that small to midsized neurons store CGRP in the trigeminal ganglion, while larger neurons contain CGRP receptor. 1 Although other CGRP-binding sites can be found in the TGVS their roles in migraine are unclear. 3, 18 For example, an in vitro study found that adrenomedullin only had an effect on cat cerebral arteries at a high concentration. 19 Another study found that, unlike CGRP, infusion of adrenomedullin failed to induce migraine in patients. 3, 20 However, we do not know at the present time if AMY1 receptors, which are CGRP binding sites, are or are not involved in migraine. 19 The brainstem is an important integration site for sensory signals from the periphery, including those from the trigeminal ganglion. 21 It is known to be activated in migraine, and several of its regions may be involved in CGRP signaling. 7, 21 Based on binding studies with a CGRP receptor antagonist, several brainstem areas have been shown to express RAMP1 and CLR. 21 As these areas involve sensory centers, cranial motor nuclei, and pathways to the hypothalamus and thalamus, this fact suggests that CGRP has a diverse effect in the brainstem. 21 Interestingly, some of these areas are not protected by the blood-brain barrier (BBB), suggesting that anti-CGRP therapeutic agents developed for migraine may not need to penetrate the central nervous system (CNS) to have an effect. 21 Trigeminal CGRP, through its roles in vasodilation, neurogenic inflammation, and peripheral sensitization, is likely to contribute to the most relevant peripheral actions in migraine. 3 The main source of CGRP in migraine is primary trigeminal afferents, as plasma-derived CGRP is unlikely to reach the ventroposterior medial thalamic nucleus because of poor penetration of the BBB. [22] [23] [24] In the periphery, afferent endings of sensory neurons innervate blood vessels in almost every organ system, but the implications of CGRP release here in relation to migraine are unclear. 3 
EVIDENCE FOR THE ROLE OF CGRP IN MIGRAINE
Important work by Goadsby and Edvinsson's group showed that during a migraine headache attack CGRP serum levels were elevated in the cranial circulation, but not in the peripheral circulation. 25 Evidence for a key role for CGRP came from the finding that while trigeminal ganglion stimulation led to increased CGRP levels in the cranial circulation, these levels could be markedly reduced following the administration of either sumatriptan or dihydroergotamine. 26 Additional work showed that plasma CGRP concentration decreased parallel to headache intensity during sumatriptan treatment and that the decrease in CGRP predicted the effectiveness of antimigraine drug therapy. 27 A causative role for CGRP in migraine was suggested from studies showing that intravenous injections of CGRP could trigger migraine-like attacks in migraine patients but not in healthy volunteers.
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The exact mechanism underlying this difference in susceptibility to CGRP remains unclear. 30, 31 Further studies have shown CGRP serum levels to be elevated during attacks for various types of migraine and other primary headaches, 32 cluster headache, 33 chronic paroxysmal hemicrania.
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The subsequent development of selective non-peptide CGRP receptor antagonists through clinical trials provided additional proof of the importance of CGRP in migraine. 31 
ANTIMIGRAINE EFFECTS OF CGRP INHIBITION -EVIDENCE FROM SMALL-MOLECULE "GEPANT" THERAPIES
Although the triptan group of drugs provides effective relief from acute migraine attacks for many patients, a substantial number of affected individuals are unresponsive. 35 The search for a new therapeutic approach to managing migraine led to the targeting of CGRP receptors. 35, 36 The "gepant" class of drugs are small-molecule CGRP receptor blockers that were developed for the treatment of acute migraine. 35 The gepants have demonstrated efficacy in clinical trials and their action suggests they act at several sites in the trigeminal system and in the CNS, which results in pain relief. 35 Importantly, the gepants do not cause direct vasoconstriction, which, therefore, avoids one of the major limitations of using triptans. 35, 37, 38 Head-to-head clinical trials with triptans for acute treatment of migraine attacks showed the efficacy of gepants to be comparable to that of triptans and superior to placebo. 36, 39 Despite the initially promising efficacy results with the gepants, further trial results revealed certain safety limitations. Available data from an exploratory study with telcagepant suggested efficacy for migraine prevention, but hepatotoxicity concerns led to termination of its development. 40 Hepatotoxicity risk was found to be strongly related to the frequency and duration of telcagepant treatment. 40 Another gepant, MK-3207, which was effective in acute migraine attacks was also terminated after liver test abnormalities in some subjects in extended phase I clinical pharmacology studies. 40 However, the pattern of safety findings with MK-3207 differed from those with telcagepant, suggesting that the hepatotoxic effects might not be a class-wide effect. 40 The telcagepant liver issue is today considered as an off-target effect due to a byproduct that forms during breakdown of the molecule; novel gepants do not form this hepatotoxic metabolite. 41 Olcegepant (BIBN4096BS) showed efficacy in phase II clinical trials, but was not commercialized as it was unsuitable for oral administration. 37, 41 Positive phase IIa data were obtained for BI44370 and rimagepant (BMS-927711), but further data on these molecules have not been presented. 42 Despite the setbacks for certain molecules in the class, two oral gepants (with distinct chemical backbones to telcagepant and MK-3207 and that do not form the hepatotoxic metabolite) remain in clinical development. Ubrogepant is being investigated in two phase III trials for acute treatment of migraine attack 43, 44 and in a long-term extension study, 45 while atogepant/MK-8031/AGN-241689 is being investigated for episodic migraine prevention in a phase II/III trial. 46 There are reports that the gepants pass poorly through the BBB, but it is still not clear how they exert their anti-migraine action. 35, 38 One study used a CGRP receptor positron emission tomography (PET) tracer to quantify the in vivo level of central CGRP receptor occupancy with doses of telcagepant. 47 The doses of telcagepant considered to be efficacious were based on phase III trials. Studies with human subjects showed that while it was possible to achieve central CGRP receptor occupancy at supratherapeutic doses of telcagepant, the usual, lower doses of telcagepant used to achieve efficacy did not involve central CGRP receptor occupancy. 47 It was concluded that central occupancy of CGRP receptors is not required for efficacy in patients with migraine. 47 Further studies with more brain-penetrant CGRP antagonists are needed to put such findings into perspective. 47 Although antagonism of the CGRP receptor with the gepants has shown to be effective in relieving migraine pain and potentially preventing migraine attacks, the safety concerns seen with some molecules in this class have prompted a search for more selective therapies, with improved tolerability and safety profiles. Progress with respect to alternative monoclonal antibody (mAb) approaches has attracted wide interest. 
DEVELOPMENT OF MONOCLONAL ANTIBODY THERAPIES
Given that some of the CGRP receptor localization is outside the BBB and that the gepants can still be effective by acting outside the BBB, large molecules that do not readily cross the BBB such as mAbs could be envisaged for migraine therapy. mAbs have excellent target specificity, thereby minimizing off-target toxicities common to small molecules. 52 As mAbs have reasonably long terminal half-lives, less frequent dosing is possible, thereby offsetting the need for frequent dosing. 52 While typical migraine-preventive medications may involve one to three times daily oral dosing, a mAb therapeutic might be administered once a month or even less frequently. 52 Nevertheless, there are some safety issues specific to the administration of mAbs, including infusion reactions, site administration reactions, as well as more systemic immunologic effects. 52 While there is the potential for patients treated with a mAb to experience an immune response against the therapeutic protein, humanization of most mAbs has greatly reduced their immunogenic potential. 52 Four mAbs are currently being investigated in clinical trials for migraine prevention (Table 2) . Eptinezumab employs the proprietary MabXpress antibody production technology which is considered to improve the efficiency of producing large molecule therapeutics. 46, 88, 89 Erenumab was generated using the XenoMouse technology which delivers fully human mAbs. 90, 91 Galcanezumab was produced in BALB/c mice immunized with human CGRP conjugated to ovalbumin. Antibodies (Abs) were screened for the ability to bind human CGRP and the selected Abs were humanized and optimized for affinity and developability. 81, 92 Fremanezumab was raised in BALB/c mice immunized with human CGRP conjugated to keyhole limpet hemocyanin, humanized and optimized. 93, 94 It binds the C-terminal epitope within amino acids 8-37 of CGRP and prevents CGRP from interacting with the receptor. 50 Initially developed as an intravenous agent, it has been reformulated to allow subcutaneous administration. Anti-CGRP mAbs (such as eptinezumab, galcanezumab, fremanezumab) could remove the excess CGRP that is released at perivascular trigeminal sensory nerve fibers, while anti-CGRP receptor mAbs (such as erenumab) block the ligand from binding the CGRP receptor. 52 A potential advantage of a mAb targeting the CGRP receptor instead of the ligand could be to avoid interference with the function of other CGRP-binding receptors. 95 However, it must also be borne in mind that this approach could also reduce potential efficacy, should other CGRP-binding receptors be involved in migraine. Limited in vitro information has emerged on the selective targeting of the CGRP ligand by galcanezumab, eptinezumab and fremanezumab. 49, 51, 96 Using plasmon resonance studies, subtle binding differences have been reported that may have clinical implications in terms of duration, intensity, and drug efficacy. 49, 51, 96 Galcanezumab was found to be an incomplete antagonist of CGRP, showing rapid target engagement and dissociation. 51, 96 This might enable significant levels of CGRP to be free to engage with the receptor. 51, 96 In contrast, eptinezumab and fremanezumab showed more rapid engagement of CGRP to inactivate the peptide and showed an extremely slow dissociation. 49, 51, 96 These antibodies would be expected to have a rapid onset of action and long-lived clinical activity. 49, 51, 96 Another finding was that, at equivalent circulating concentrations, eptinezumab engaged and stopped CGRP activities twice as rapidly as fremanezumab, but whether these reported distinctions have a bearing on the clinical management of migraine with these antibodies is not yet clear. 51, 96 To date, galcanezumab, eptinezumab and fremanezumab have shown promising efficacy in clinical trials and further data are awaited. 51 Erenumab is the only mAb targeting the CGRP receptor (Fig. 2) and is believed to occupy the binding site of CGRP within the receptor, between the subunits. 90 As the ligand-binding site on the CGRP receptor complex is broad, an antibody that can span the distance between these receptor subunits can provide effective blockade. 90 Erenumab functions as a competitive inhibitor of CGRP, binding the CGRP receptor with high affinity and potency, in a reversible manner. 90, 97 Erenumab is more potent than telcagepant but comparable to MK-3207. 97 It is highly selective for the CGRP receptor (RAMP1-CLR), more so than for other receptors of the family including the adrenomedullin, calcitonin, and amylin receptors. 90 In contrast to the selectivity displayed by erenumab, telcagepant displays inhibition of both the CGRP and the AMY1 receptors.
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CLINICAL EVIDENCE FOR ANTIBODIES IN DEVELOPMENT TARGETING THE CGRP PATHWAY To date, the clinical evidence has confirmed the efficacy of preventive strategies using mAbs by showing reduced migraine (or headache) days per month from baseline along with favorable safety (Table 3) . 53, 54, 58, 59, 61, 70, 71, 73, 80, 81, 99 Collectively, the trial data show promise, in that all the mAbs exhibit low to no side effects while having efficacy in both EM and CM. Furthermore, available long-term (< 1 year duration) data indicate that efficacy is maintained. In fact, anecdotal reports from patients suggest that upon termination of the clinical trial there is a recurrence of headache, much to the dismay of the patients. Also, it has recently been reported that fremanezumab is a safe and effective add-on treatment for migraine patients being concomitantly treated with other prophylactic medications. 100 Ongoing long-term studies for these mAbs will be important to confirm the promising efficacy and safety profiles reported to date, and the durability of preventive effects. At present, the results of one randomized controlled erenumab trial with 6-month therapy and a prespecified 1-year interim analysis of an open-label extension trial of patients with EM are available. 61, 65 These data corroborate the clinical benefit of erenumab with an overall safety profile similar to that of placebo.
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CONCLUSION
The CGRP pathway is now known to be key to migraine. Detailed studies have revealed the wide expression of CGRP and CGRP receptor in the TGVS.
1,2 CGRP is released during acute attacks of migraine and cluster headache, correlating with clinical symptoms. 5, 25 In addition, blocking the CGRP pathway at extracerebral sites aborts acute attacks (eg, with gepants) and enables prophylaxis of frequent episodic and CM (eg, with mAbs). The safety profile with mAbs is favorable, with no serious side effects recorded and no circulatory effects. Data emerging from trials with mAbs suggest that this specific blockade of the CGRP pathway may provide a safe and specific novel therapeutic approach in migraine and so are attracting great interest. 53, 54, 58, 59, 61, 70, 71, 73, 80, 81, 99 Acknowledgments: The author thanks Faiz Kermani (Health Interactions) for medical editorial assistance with this manuscript.
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